The Bio Report

The discovery and cell line development of biotherapeutics has been traditionally a distinct process. Absci is taking what it describes as a more wholistic approach by collapsing the process down and addressing the functionality and manufacturability of therapeutic candidates simultaneously. We spoke to Sean McClain, founder and CEO of AbSci, about how it is using AI and synthetic biology to reinvent the discovery process, how this is expanding the therapeutic potential of proteins, and how it translates into time and cost benefits.